In this landscape, it is a filing that combines process-characterization language, such as critical process parameter or design space definition, with a structured method like design of experiments, criticality assessment, edge-of-failure testing, multivariate modelling, control strategy definition or life-cycle validation. This combination shows up heavily in biologics and pharmaceutical process development but also in industrial process-control filings that borrow the same statistical vocabulary. The 2,180 records in this dataset were identified by searching for both elements together, not either alone.

The dataset ranks 100 companies by record count, with a single leader holding 88 records well ahead of the fifth-place figure of 40 and tenth-place figure of 36. Even so, the top 5 assignees combined cover only 13.3% of all 2,180 records and the top 10 cover 22.1%, meaning most of the field’s activity sits with filers outside the ranked leaders. This is a landscape with one clear leader but no dominant oligopoly.

Filing rose from 112 records in 2017 to a peak of 185 in 2021, then eased to 139 by 2024, a -25% change over that three-year span. Figures for 2025 and 2026 look lower still, but publication typically lags actual filing by around 18 months, so those recent years are incomplete rather than proof of a real slowdown. The safest read is that activity cooled somewhat after 2021 but the most current trend line will only be clear once later publications catch up.